<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739244</url>
  </required_header>
  <id_info>
    <org_study_id>SYL040012_III</org_study_id>
    <nct_id>NCT01739244</nct_id>
  </id_info>
  <brief_title>Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma</brief_title>
  <official_title>Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sylentis, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sylentis, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this dose-finding clinical trial is to evaluate the systemic tolerability, local&#xD;
      tolerability and intraocular pressure lowering effect of three different doses of SYL040012&#xD;
      in subjects with ocular hypertension or open-angle glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in AUC between IOP Curve Obtained at the Established Time Points and the Same Curve Performed at Baseline Period</measure>
    <time_frame>14 days + (4-7 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Simple Corneal and Conjunctival Evaluation</measure>
    <time_frame>15 days + (3-6 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity, anterior segment and ocular fundus examination as measures of local tolerability.</measure>
    <time_frame>14 days + (4-7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical exploration and laboratory tests as measurements of general tolerability</measure>
    <time_frame>14 days + (4-7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events Appearance</measure>
    <time_frame>14 days + (4-7 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>SYL040012 eye drops dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular topical administration of SYL040012 eye drops dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYL040012 eye drops dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular topical administration of SYL040012 eye drops dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYL040012 eye drops dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular topical administration of SYL040012 eye drops dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ocular topical administration of placebo eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL040012</intervention_name>
    <description>Ocular topical administration of SYL040012 for 14 consecutive days</description>
    <arm_group_label>SYL040012 eye drops dose A</arm_group_label>
    <arm_group_label>SYL040012 eye drops dose B</arm_group_label>
    <arm_group_label>SYL040012 eye drops dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ocular topical administration of placebo for 14 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must provide signed informed consent prior to participation in any&#xD;
             study-related procedures.&#xD;
&#xD;
          -  Male and female subjects in good or fair general health as assessed by the&#xD;
             investigator.&#xD;
&#xD;
          -  ≥18 years of age.&#xD;
&#xD;
          -  Previous history or newly diagnosed elevated IOP (≥21 mmHg) with or without open-angle&#xD;
             glaucoma in both eyes.&#xD;
&#xD;
          -  Normal result, or result typical for open-angle glaucoma of the following assessments&#xD;
             in both eyes or available results in writing within the last 3 months prior to&#xD;
             baseline period i.e. up to 4 months before Day 1, on condition that no new ocular&#xD;
             signs or symptoms (e.g. marked deterioration of vision, eye pain) has occurred since&#xD;
             then which would justify a repeat examination:&#xD;
&#xD;
          -  Visual field 24-2 or equivalent&#xD;
&#xD;
          -  Optical coherence tomography (OCT)&#xD;
&#xD;
          -  Best corrected visual acuity ≥0.5 (20/40) on the Snellen chart, or ≤ 0.3 logMAR&#xD;
&#xD;
          -  Schirmer test (lacrimation)&#xD;
&#xD;
          -  Funduscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding females or those with a positive pregnancy test. Females of&#xD;
             childbearing potential who will not use a medically acceptable contraceptive method&#xD;
             from selection and during the hole study.&#xD;
&#xD;
          -  Females of childbearing potential not willing to use a medically acceptable&#xD;
             contraceptive method from enrolment until after the follow-up visit.&#xD;
&#xD;
          -  Any current disease or condition that might compromise the respiratory,&#xD;
             cardiovascular, endocrine, neurological, haematological, renal, or gastrointestinal&#xD;
             function.&#xD;
&#xD;
          -  Previous chronic processes or with rebound characteristics that could interfere with&#xD;
             the study according to the investigator's judgment.&#xD;
&#xD;
          -  Body temperature.&#xD;
&#xD;
          -  Intolerability of any components of SYL040012 or placebo.&#xD;
&#xD;
          -  Unable to comply with the clinical trial requirements as judged by the investigator.&#xD;
&#xD;
          -  Beta blockers or corticosteroids use (other than cutaneous or intra-articular) for the&#xD;
             treatment of concurrent diseases, even if sporadically, or any ocular or nasal&#xD;
             vasoconstrictor treatment in the last 15 days prior to the first investigational&#xD;
             product administration&#xD;
&#xD;
          -  Previous refractive surgery; cataract extraction in the last 6 months&#xD;
&#xD;
          -  Previous surgery for glaucoma.&#xD;
&#xD;
          -  Participation in a clinical trial within 2 months before the enrolment visit&#xD;
&#xD;
          -  Use of any other investigational product within 60 days before the enrolment visit.&#xD;
&#xD;
          -  Other drugs for the treatment of concurrent diseases are allowed. However, their&#xD;
             dosages should be kept constant throughout the study.&#xD;
&#xD;
          -  Use of contact lenses in the last 7 days prior to the first investigational product&#xD;
             administration and wearing contact lenses throughout the trial&#xD;
&#xD;
          -  History of ocular infection or inflammation within the last 3 months before the&#xD;
             enrolment visit&#xD;
&#xD;
          -  Angle-closure or pigmentary glaucoma.&#xD;
&#xD;
          -  Chronic or current acute eye diseases such as scleritis, uveitis, blepharitis,&#xD;
             conjunctivitis, or ocular Herpes simplex virus infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>East Tallin Central Hospital</name>
      <address>
        <city>Tallin</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Clinic Dr. Krista Turman</name>
      <address>
        <city>Tallin</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català de Retina</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Oftalmobiología Aplicada</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 12, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2012</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Open Angle Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>IOP</keyword>
  <keyword>RNAi</keyword>
  <keyword>siRNA</keyword>
  <keyword>beta inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

